Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH drug portfolio — 119 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

AbbVie Deutschland GmbH pipeline

Portfolio lens on 119 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

AbbVie Deutschland GmbH drug portfolio — 119 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

119 compounds

  1. abacavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved.

  2. acalabrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  3. acalabrutinib maleate

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  4. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  5. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  6. administration

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  7. aflibercept

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Placenta growth factor.

    Target
    Placenta growth factor
    Mechanism
    Placenta growth factor inhibitor

  8. aldesleukin

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor agonist

  9. amivantamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor inhibitor

  10. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  11. atogepant

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Calcitonin gene-related peptide type 1 receptor.

    Target
    Calcitonin gene-related peptide type 1 receptor
    Mechanism
    Calcitonin gene-related peptide type 1 receptor antagonist

  12. azacitidine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 3A inhibitor

  13. bendamustine

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  14. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  15. bimatoprost

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.

    Target
    Prostaglandin F2-alpha receptor
    Mechanism
    Prostanoid FP receptor agonist

  16. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  17. brimonidine

    Dermatologicals (D11)

    Dermatologicals (D11) compound in AbbVie Deutschland GmbH's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.

    Mechanism
    Adrenergic receptor alpha-2 agonist

  18. brimonidine tartrate

    US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.

    Target
    Adrenergic receptor alpha-2
    Mechanism
    Adrenergic receptor alpha-2 agonist

  19. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  20. capsule

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  21. capsules

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  22. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  23. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  24. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  25. celecoxib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.

    Target
    Prostaglandin G/H synthase 2
    Mechanism
    Cyclooxygenase-2 inhibitor

  26. chloride

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  27. ciprofloxacin

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  28. ciprofloxacin hydrochloride

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  29. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  30. combination

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  31. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  32. cytarabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  33. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  34. deucravacitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.

    Target
    Non-receptor tyrosine-protein kinase TYK2
    Mechanism
    Tyrosine-protein kinase TYK2 negative allosteric modulator

  35. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  36. diphenhydramine

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  37. diphenhydramine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  38. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  39. dose

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  40. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  41. dupilumab

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.

    Target
    Interleukin-4 receptor subunit alpha
    Mechanism
    Interleukin-4 receptor subunit alpha antagonist

  42. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  43. elotuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: SLAM family member 7.

    Target
    SLAM family member 7
    Mechanism
    SLAM family member 7 inhibitor

  44. epcoritamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  45. epithelial

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  46. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  47. fingolimod

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.

    Mechanism
    Sphingosine 1-phosphate receptor binding agent

  48. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  49. fluprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  50. folate

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  51. folinic acid

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  52. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  53. hema-

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  54. ibrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  55. infusion

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  56. injection

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  57. intravenous

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  58. intravenously

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  59. irinotecan

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  60. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  61. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  62. lenvatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  63. lenvatinib mesylate

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.

    Target
    Vascular endothelial growth factor receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  64. matching

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  65. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  66. mirvetuximab

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Molecular target: Folate receptor alpha.

    Target
    Folate receptor alpha
    Mechanism
    Folate receptor alpha binding agent

  67. mirvetuximab soravtansine

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: Folate receptor alpha.

    Target
    Folate receptor alpha
    Mechanism
    Tubulin inhibitor

  68. monotherapy

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  69. obinutuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  70. ofloxacin

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  71. omid

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  72. osimertinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  73. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  74. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  75. panitumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  76. paracetamol

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  77. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  78. pemetrexed

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  79. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  80. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  81. peritoneal

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  82. pirtobrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  83. placebo

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  84. polatuzumab vedotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: B-cell antigen receptor complex-associated protein beta chain.

    Target
    B-cell antigen receptor complex-associated protein beta chain
    Mechanism
    B-cell antigen receptor complex-associated protein beta chain binding agent

  85. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  86. powder

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  87. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  88. prednisolone acetate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  89. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  90. ranibizumab

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  91. regimen

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  92. risankizumab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: Interleukin-23.

    Target
    Interleukin-23
    Mechanism
    Interleukin-23 inhibitor

  93. rituximab-abbs

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  94. ruxolitinib

    Dermatologicals (D11)

    US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.

    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  95. selinexor

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Exportin-1.

    Target
    Exportin-1
    Mechanism
    Exportin-1 inhibitor

  97. solution

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  98. sorafenib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  99. stro-

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  100. subcutaneous

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  101. sulfasalazine

    US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.

    Target
    Polyunsaturated fatty acid 5-lipoxygenase
    Mechanism
    Arachidonate 5-lipoxygenase inhibitor

  102. suspension

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  103. t-cell

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  104. tablet

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  105. tablets

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  106. taxane

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  107. telisotuzumab

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Molecular target: Hepatocyte growth factor receptor.

    Target
    Hepatocyte growth factor receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  109. therapy

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  110. timolol

    US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.

    Target
    Beta-1 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor antagonist

  111. tocilizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit inhibitor

  112. treatment

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records.

  113. tremelimumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in AbbVie Deutschland GmbH's portfolio. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  114. trifluridine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  115. upadacitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Tyrosine-protein kinase TYK2 inhibitor.

    Mechanism
    Tyrosine-protein kinase TYK2 inhibitor

  116. vedolizumab

    US regulatory status: approved. Molecular target: Integrin alpha-4/beta-7.

    Target
    Integrin alpha-4/beta-7
    Mechanism
    Integrin alpha-4/beta-7 inhibitor

  117. venetoclax

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.

    Target
    Apoptosis regulator Bcl-2
    Mechanism
    Apoptosis regulator Bcl-2 inhibitor

  118. vincristine

    Development asset linked to AbbVie Deutschland GmbH in public FDA and regional records. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  119. vincristine sulfate

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.